181 related articles for article (PubMed ID: 15228236)
1. Monocyte-mediated acute renal rejection after combined treatment with preoperative Campath-1H (alemtuzumab) and postoperative immunosuppression.
Zhang PL; Malek SK; Prichard JW; Lin F; Yahya TM; Schwartzman MS; Latsha RP; Skaletsky M; Norfolk ER; Brown RE; Hartle JE; Potdar S
Ann Clin Lab Sci; 2004; 34(2):209-13. PubMed ID: 15228236
[TBL] [Abstract][Full Text] [Related]
2. C4d positivity is often associated with acute cellular rejection in renal transplant biopsies following Campath-1H (Alemtuzumab) induction.
Zhang PL; Malek SK; Blasick TM; Pennington JR; Masker KK; Lun M; Potdar S
Ann Clin Lab Sci; 2007; 37(2):121-6. PubMed ID: 17522366
[TBL] [Abstract][Full Text] [Related]
3. Campath-1H use in pediatric renal transplantation.
Bartosh SM; Knechtle SJ; Sollinger HW
Am J Transplant; 2005 Jun; 5(6):1569-73. PubMed ID: 15888071
[TBL] [Abstract][Full Text] [Related]
4. Acute cellular rejection predominated by monocytes is a severe form of rejection in human renal recipients with or without Campath-1H (alemtuzumab) induction therapy.
Zhang PL; Malek SK; Prichard JW; Lin F; Yahya TM; Schwartzman MS; Latsha RP; Norfolk ER; Blasick TM; Lun M; Brown RE; Hartle JE; Potdar S
Am J Transplant; 2005 Mar; 5(3):604-7. PubMed ID: 15707416
[TBL] [Abstract][Full Text] [Related]
5. Campath-1H in renal transplantation: The University of Wisconsin experience.
Knechtle SJ; Fernandez LA; Pirsch JD; Becker BN; Chin LT; Becker YT; Odorico JS; D'alessandro AM; Sollinger HW
Surgery; 2004 Oct; 136(4):754-60. PubMed ID: 15467659
[TBL] [Abstract][Full Text] [Related]
6. Recipient memory-like lymphocytes remain unresponsive to graft antigens after CAMPATH-1H induction with reduced maintenance immunosuppression.
Trzonkowski P; Zilvetti M; Friend P; Wood KJ
Transplantation; 2006 Nov; 82(10):1342-51. PubMed ID: 17130784
[TBL] [Abstract][Full Text] [Related]
7. Immunophenotypic analysis of cellular infiltrate of renal allograft biopsies in patients with acute rejection after induction with alemtuzumab (Campath-1H).
Gallon L; Gagliardini E; Benigni A; Kaufman D; Waheed A; Noris M; Remuzzi G
Clin J Am Soc Nephrol; 2006 May; 1(3):539-45. PubMed ID: 17699257
[TBL] [Abstract][Full Text] [Related]
8. Alemtuzumab (Campath-1H) induction therapy and dendritic cells: Impact on peripheral dendritic cell repertoire in renal allograft recipients.
Kirsch BM; Haidinger M; Zeyda M; Böhmig GA; Tombinsky J; Mühlbacher F; Watschinger B; Hörl WH; Säemann MD
Transpl Immunol; 2006 Nov; 16(3-4):254-7. PubMed ID: 17138063
[TBL] [Abstract][Full Text] [Related]
9. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells.
Hale G; Jacobs P; Wood L; Fibbe WE; Barge R; Novitzky N; Toit C; Abrahams L; Thomas V; Bunjes D; Duncker C; Wiesneth M; Selleslag D; Hidajat M; Starobinski M; Bird P; Waldmann H
Bone Marrow Transplant; 2000 Jul; 26(1):69-76. PubMed ID: 10918407
[TBL] [Abstract][Full Text] [Related]
10. Experience with Alemtuzumab (Campath-1H) as induction agent in renal transplantation followed by steroid-free immunosuppression.
Baez Y; Giron F; Niño-Murcia A; Rodríguez J; Salcedo S
Transplant Proc; 2008 Apr; 40(3):697-9. PubMed ID: 18454990
[TBL] [Abstract][Full Text] [Related]
11. Campath-1H (alemtuzumab) as an induction agent for the prevention of graft rejection and preservation of renal function in kidney transplant patients: Philippine 3-year follow-up.
Muñoz AS; Cabanayan-Casasola CB; Danguilan RA; Padua FB; Ona ET
Transplant Proc; 2008 Sep; 40(7):2230-3. PubMed ID: 18790200
[TBL] [Abstract][Full Text] [Related]
12. Alemtuzumab induction in kidney transplantation: clinical results and impact on T-regulatory cells.
Morales J; Bono MR; Fierro A; Iñiguez R; Zehnder C; Rosemblatt M; Calabran L; Herzog C; Benavente D; Aguiló J; Pefaur J; Alba A; Ferrario M; Simon W; Contreras L; Buckel E
Transplant Proc; 2008 Nov; 40(9):3223-8. PubMed ID: 19010240
[TBL] [Abstract][Full Text] [Related]
13. The use of Campath-1H as induction therapy in renal transplantation: preliminary results.
Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roohipour R; Carreno MR; Roth D; Ruiz P; Kupin W; Rosen A; Esquenazi V; Tzakis AG; Miller J
Transplantation; 2004 Aug; 78(3):426-33. PubMed ID: 15316372
[TBL] [Abstract][Full Text] [Related]
14. Impact on T-cell depletion and CD34+ cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G.
Williams RJ; Clarke E; Blair A; Evely R; Hale G; Waldmann H; Brookes S; Pamphilon DH
Cytotherapy; 2000; 2(1):5-14. PubMed ID: 12042050
[TBL] [Abstract][Full Text] [Related]
15. Alemtuzumab induction in deceased donor kidney transplantation.
Shin M; Song SH; Kim JM; Kwon CH; Joh JW; Lee SK; Kim SJ
Transplant Proc; 2011; 43(6):2365-78. PubMed ID: 21839271
[TBL] [Abstract][Full Text] [Related]
16. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H).
Kirk AD; Hale DA; Mannon RB; Kleiner DE; Hoffmann SC; Kampen RL; Cendales LK; Tadaki DK; Harlan DM; Swanson SJ
Transplantation; 2003 Jul; 76(1):120-9. PubMed ID: 12865797
[TBL] [Abstract][Full Text] [Related]
17. Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation.
Thomas PG; Woodside KJ; Lappin JA; Vaidya S; Rajaraman S; Gugliuzza KK
Transplantation; 2007 Jun; 83(11):1509-12. PubMed ID: 17565326
[TBL] [Abstract][Full Text] [Related]
18. Reversal of acute cellular rejection after renal transplantation with Campath-1H.
Basu A; Ramkumar M; Tan HP; Khan A; McCauley J; Marcos A; Fung JJ; Starzl TE; Shapiro R
Transplant Proc; 2005 Mar; 37(2):923-6. PubMed ID: 15848576
[TBL] [Abstract][Full Text] [Related]
19. Treatment of refractory acute rejection in a lung transplant recipient with campath 1H.
Reams BD; Davis RD; Curl J; Palmer SM
Transplantation; 2002 Sep; 74(6):903-4. PubMed ID: 12364881
[No Abstract] [Full Text] [Related]
20. Treatment of simultaneous acute antibody-mediated rejection and acute cellular rejection with alemtuzumab in kidney transplantation: a case report.
Jirasiritham S; Khunprakant R; Techawathanawanna N; Jirasiritham S; Mavichak V
Transplant Proc; 2010 Apr; 42(3):987-9. PubMed ID: 20430222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]